Parkinson's Institute Team Uses CRISPR/Cas9 Capture and PacBio Sequencing to ID Repeat Expansions Standard genetic testing involved repeat prime PCR, which identified a repeat expansion in the ATXN10 gene in each affected family member. Repeat expansions in the ATXN10 gene have been implicated in SCA, but have not previously been linked to Parkinson's disease, so the researchers wanted to look deeper. Because the PCR-based technology could not span the entire repeat, the team turned to PacBio for its long reads, and the firm suggested using the CRISPR/Cas9 technology it was developing as a target enrichment method.
Such a target enrichment scheme is advantageous because it does not require amplification, "which is especially important in error-prone regions with repeat expansions," Schüle said. It enables regions that are difficult to amplify to be targeted and sequenced.
In order to use CRISPR/Cas9 for target enrichment, genomic DNA is first fragmented and a PacBio adaptor known as a SMRTbell is attached, per the standard PacBio library prep protocol, Jonas Korlach, PacBio's chief scientific officer, explained. Then, guide RNAs target and selectively cut just outside the region of interest. That generates target molecules that have one end with the original adaptor and a second end containing the sequence cut by Cas9. Next, a capture adaptor is ligated onto the cut end, so that only molecules containing the targeted region have those capture adaptors. And finally, magnetic beads and probes are used to capture just the target molecules, while the remaining DNA is washed away. The target molecules are then sequenced. https://www.genomeweb.com/sequencing/parkinsons-institute-team-uses-crisprcas9-capture-and-pacbio-sequencing-id-repeat
Recent PACB News
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 10:54:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 10:52:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 10:06:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:07:28 PM
- PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results • PR Newswire (US) • 02/15/2024 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM